Cargando…

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies

Maintaining bone health remains a clinical challenge in patients with prostate cancer (PC) who are at risk of developing metastatic bone disease and increased bone loss due to hormone ablation therapy. In patients with cancer-treatment induced bone loss (CTIBL), antiresorptive agents have been shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Todenhöfer, Tilman, Stenzl, Arnulf, Hofbauer, Lorenz C., Rachner, Tilman D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329828/ https://www.ncbi.nlm.nih.gov/pubmed/25802521 http://dx.doi.org/10.1155/2015/838202

Ejemplares similares

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review
por: Walz, Simon, et al.
Publicado: (2020)

Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer
por: Harland, Niklas, et al.
Publicado: (2021)

From bone to breast and back - the bone cytokine RANKL and breast cancer
por: Hofbauer, Lorenz C, et al.
Publicado: (2011)

Fatal attraction: why breast cancer cells home to bone
por: Hofbauer, Lorenz C, et al.
Publicado: (2008)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
por: Göbel, Andy, et al.
Publicado: (2021)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients
por: Rachner, Tilman D, et al.
Publicado: (2014)

Assessment of a new point-of-care system for detection of prostate specific antigen
por: Rausch, Steffen, et al.
Publicado: (2016)

Mice lacking DKK1 in T cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss
por: Lehmann, Juliane, et al.
Publicado: (2021)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Benad-Mehner, Peggy, et al.
Publicado: (2013)

Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer
por: Russo, Giorgio Ivan, et al.
Publicado: (2019)

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
por: Göbel, Andy, et al.
Publicado: (2019)

Preface to “Management of advanced genitourinary malignancies”
por: Todenhöfer, Tilman
Publicado: (2021)

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB
por: Todenhöfer, Tilman, et al.
Publicado: (2021)

Skeletal endocrinology: where evolutionary advantage meets disease
por: Jaschke, Nikolai, et al.
Publicado: (2021)

Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study
por: Horstmann, Marcus, et al.
Publicado: (2014)

Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
por: Browne, Andrew J., et al.
Publicado: (2017)

Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria
por: Hennenlotter, Joerg, et al.
Publicado: (2011)

Diabetes and the Prostate: Elevated Fasting Glucose, Insulin Resistance and Higher Levels of Adrenal Steroids in Prostate Cancer
por: Lutz, Stefan Zoltán, et al.
Publicado: (2022)

Long-term results after endoscopic VUR-treatment using dextranomer / hyaluronic acid copolymer – 5-year experience in a single-center
por: Seibold, Joerg, et al.
Publicado: (2011)

Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems
por: Wei, Yi, et al.
Publicado: (2022)

Regulation of VEGF by mevalonate pathway inhibition in breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2013)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer
por: Heni, Martin, et al.
Publicado: (2012)

Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma
por: Todenhöfer, Tilman, et al.
Publicado: (2012)

Circulating and Disseminated Tumor Cells in the Management of Advanced Prostate Cancer
por: Kruck, Stephan, et al.
Publicado: (2012)

Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis
por: Klotz, Daniel Martin, et al.
Publicado: (2022)

Role of WNT5A receptors FZD5 and RYK in prostate cancer cells
por: Thiele, Stefanie, et al.
Publicado: (2018)

Human Prostate Cancer Is Characterized by an Increase in Urea Cycle Metabolites
por: Franko, Andras, et al.
Publicado: (2020)

Intracorporeal ileal ureter replacement using laparoscopy and robotics
por: Sim, Allen, et al.
Publicado: (2014)

AUTHOR'S REPLY
por: Sim, Allen, et al.
Publicado: (2014)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
por: Wilke, Maria, et al.
Publicado: (2014)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers
por: Rachner, Tilman D., et al.
Publicado: (2015)

Androgen receptor overexpression in prostate cancer in type 2 diabetes
por: Lutz, Stefan Zoltán, et al.
Publicado: (2017)

Controversies in the management of advanced prostate cancer
por: Tyrrell, C J
Publicado: (1999)

Bone biopsy in chronic kidney disease: still an option?
por: Drueke, Tilman B.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pb9lh5tsav4n2sj45datjhsiks